Natixis Advisors LLC Purchases 281,098 Shares of Johnson & Johnson (NYSE:JNJ)

Key Points

• Natixis Advisors LLC increased its position in Johnson & Johnson by 27.5% during the first quarter, now holding over 1.3 million shares valued at approximately $216 million.
• Johnson & Johnson reported earnings per share of $2.77 for the last quarter, beating estimates, with revenues up 5.8% year-over-year.
• The company declared a quarterly dividend of $1.30 per share, with a yield of 3.09%, payable on September 9th.

Natixis Advisors LLC grew its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 27.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,303,240 shares of the company's stock after purchasing an additional 281,098 shares during the quarter. Natixis Advisors LLC owned approximately 0.05% of Johnson & Johnson worth $216,129,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Conquis Financial LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $33,000. Bernard Wealth Management Corp. acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $36,000. Highline Wealth Partners LLC lifted its position in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares during the period. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson during the 1st quarter valued at $49,000. Finally, Capital A Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at $50,000. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on JNJ shares. Guggenheim restated a "neutral" rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Royal Bank Of Canada increased their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Bank of America raised their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday, July 17th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Trading Down 1.5%

NYSE:JNJ traded down $2.50 during trading hours on Thursday, hitting $164.76. The company had a trading volume of 9,876,897 shares, compared to its average volume of 8,007,298. The company has a market capitalization of $396.81 billion, a PE ratio of 17.62, a price-to-earnings-growth ratio of 2.13 and a beta of 0.41. The stock has a 50-day moving average price of $157.18 and a 200 day moving average price of $156.44. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.82 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.